Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Nonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...

About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver ...

In patients with evidence of liver dysfunction or injury, consideration should be given to performance of liver biopsy for diagnosis ... alcoholic fatty liver, alcoholic hepatitis, and cirrhosis.

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Nonalcoholic fatty liver disease (NAFLD ... is the most common cause of death in NAFLD patients. Liver biopsy and noninvasive markers should be used to stage and grade nonalcoholic steatohepatitis ...

Medically reviewed by Oliver Eng, MD Alanine aminotransferase (ALT) is an enzyme primarily found in your liver. An enzyme is ...

The global elastography imaging market is experiencing significant growth, with projections indicating that the industry will ...

Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns.